Results 171 to 180 of about 164,834 (264)

Senotherapeutics for Knee Osteoarthritis

Medicinal Research Reviews, EarlyView.
ABSTRACT Osteoarthritis (OA) is a chronic disease that imposes a significant economic burden and deteriorates quality of life. Nevertheless, current therapeutic options for OA are limited to symptomatic remedies. As such, there is a high interest in novel methods for treating or preventing OA.
Ezgi Duman, Girish Pattappa, Patrick Pann, Stephan Reppenhagen, Maximilian Rudert, Peter Angele, Denitsa Docheva   +6 more
wiley   +1 more source

[Retracted] SHIP1 is targeted by miR‑155 in acute myeloid leukemia. [PDF]

Oncol Rep
Xue H, Hua LM, Guo M, Luo JM.
europepmc   +1 more source

Exploring the Value of Quantitative Muscle Ultrasound in Neuromuscular Junction Disorders: A Pilot Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Quantitative muscle ultrasound (QMUS) is a validated technique for assessing muscle pathology, yet its role in disorders primarily affecting the neuromuscular junction (NMJ) remains unclear. This pilot study aimed to explore whether QMUS is associated with structural muscle changes in patients with acquired or genetic NMJ ...
Artor Pogosean, Maarika Liik, Nens van Alfen, Anna Rostedt Punga   +3 more
wiley   +1 more source

Impact of Frontline Treatment Strategies on Outcomes in Patients With Acute Myeloid Leukemia, Myelodysplasia-Related. [PDF]

Cancer Rep (Hoboken)
Li Y, Jin D, Fang P, Meng X, He D, Lin J, Le J, Shu W, Yang Q, He J, Cai Z.   +10 more
europepmc   +1 more source

Information Design for Early‐Stage Dose‐Finding Trials

Naval Research Logistics (NRL), EarlyView.
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley   +1 more source

Apoptosis-related gene model predicts the prognosis in patients with acute myeloid leukemia. [PDF]

Blood Sci
Pei X, Liu W, Li Y, Wei H, Wang M, Wang J.   +5 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia. [PDF]

Genes Chromosomes Cancer
García R, Xu J, Yu L, Srinivasan K, Germans SK, Weinberg O, Fuda F, Chen W, Koduru P.   +8 more
europepmc   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia. [PDF]

J Am Heart Assoc
Selvakumar S, Shetty S, Sharma AB, Zahra FT, Wang E, Koelmeyer H, Carver J, Fradley MG, Jung W, Ky B, Lefebvre B, Scherrer-Crosbie M, Wilcox NS, Wu KY, Chan O, Xie Z, Kuykendall AT, Sallman DA, Padron E, Alomar M, Cleveland JL, Mo Q, Komrokji R, Lancet JE, Yun S, Lee DH.   +25 more
europepmc   +1 more source